Many studies and articles on amenorrhea, AUB, endometrial ablation devices and techniques are available for your review.
Read Cooper's study demonstrating a 41% amenorrhea rate and 91% success rate with the NovaSure endometrial ablation procedure after one year.
A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia.
Cooper J, Gimpelson R, Laberge P, Galen D, Garza-Leal JG, Scott J, Leyland N, Martyn P, Liu J. J Am Assoc Gynecol Laparosc. 2002 Nov;9(4):418-28.
Take a look at a comparison of the NovaSure, ThermaChoice, NovaSure HydoThermablator and HerOption endometrial ablation devices.
Summary of safety and effectiveness data from FDA: a valuable source of information on the performance of global endometrial ablation devices.
Cooper J, Gimpelson RJ. J Reprod Med. 2004 Apr;49(4):267-73. Review.
Review Clark's study comparing NovaSure Endometrial Ablation to ThermaChoice III, demonstrating higher success rates and lower pain levels associated with NovaSure.
Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office: a randomized controlled trial.
Clark TJ, Samuel N, Malick S, Middleton LJ, Daniels J, Gupta JK. Obstet Gynecol. 2011 Jan;117(1):109-18.
See Penninx's study comparing NovaSure endometrial ablation to hydrothermablation, demonstrating higher success rates and lower reintervention rates with NovaSure.
Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding: a randomized controlled trial.
Penninx JP, Mol BW, Engels R, van Rumste MM, Kleijn C, Koks CA, Kruitwagen RF, Bongers MY. Obstet Gynecol. 2010 Oct;116(4):819-26.
Learn why radiofrequency ablation is a predictor for optimal treatment outcomes.
Prediction of treatment outcomes after global endometrial ablation.
El-Nashar SA, Hopkins MR, Creedon DJ, St Sauver JL, Weaver AL, McGree ME, Cliby WA, Famuyide AO. Obstet Gynecol. 2009 Jan;113(1):97-106. Erratum in: Obstet Gynecol. 2010 Mar;115(3):663.
See Gallinat's 5-year follow up of NovaSure endometrial ablation patients, demonstrating an amenorrhea rate of 75% and a success rate of 98%.
An impedance-controlled system for endometrial ablation: five-year follow-up of 107 patients.
Gallinat A. J Reprod Med. 2007 Jun;52(6):467-72
Understand why patients feel significantly less pain during and after the NovaSure ablation procedure compared to the ThermaChoice procedure.
Assessment and comparison of intraoperative and postoperative pain associated with NovaSure and ThermaChoice endometrial ablation systems.
Laberge PY, Sabbah R, Fortin C, Gallinat A. J Am Assoc Gynecol Laparosc. 2003 May;10(2):223-32.
Review Fulop's 7-year NovaSure follow up results, illustrating a 97% amenorrhea rate and 100% success rate.
NovaSure impedance controlled endometrial ablation: long-term follow-up results.
Fulop T, Rákóczi I, Barna I. J Minim Invasive Gynecol. 2007 Jan-Feb;14(1):85-90.
Compare success rates between NovaSure and ThermaChoice endometrial ablation.
Five-year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation.
Kleijn JH, Engels R, Bourdrez P, Mol BW, Bongers MY.
See Sabbah's success when treating women with intracavitary disease up to 3 cm.
Use of the NovaSure Impedance Controlled Endometrial Ablation System in patients with intracavitary disease: 12-month follow-up results of a prospective, single-arm clinical study. Sabbah R, Desaulniers G. J Minim Invasive Gynecol. 2006 Sep-Oct;13(5):467-71.